# Azitra, Inc.: financial statements, quarterly

AZTR · NYSE · CIK 1701478 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aztr.md) · [Financials](/companies/aztr/financials.md) · [Filings](/companies/aztr/filings.md) · [Insiders](/companies/aztr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aztr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [311](/filings/0001701478-24-000012.md) | [90.0 d](/filings/0001701478-25-000012.md) | [0.0](/filings/0001701478-24-000005.md) | [7.5](/filings/0001701478-25-000040.md) | [0.0](/filings/0001701478-25-000050.md) | [0.0 d](/filings/0001701478-26-000013.md) | not reported | [0.0](/filings/0001701478-25-000040.md) | [0.0](/filings/0001701478-25-000050.md) | [0.0 d](/filings/0001701478-26-000013.md) | not reported | not reported |
| Research and development | $k | [549](/filings/0001701478-24-000012.md) | [1,511 d](/filings/0001701478-25-000012.md) | [1,473](/filings/0001701478-25-000018.md) | [1,119](/filings/0001701478-25-000040.md) | [1,016](/filings/0001701478-25-000050.md) | [1,116 d](/filings/0001701478-26-000013.md) | [1,250](/filings/0001701478-26-000028.md) | [1,402](/filings/0001701478-26-000037.md) | [1,180](/filings/0001701478-25-000050.md) | [1,004 d](/filings/0001701478-26-000013.md) | [1,561](/filings/0001701478-26-000028.md) | [1,352](/filings/0001701478-26-000037.md) |
| Operating income | $k | [(1,994)](/filings/0001701478-24-000012.md) | [(2,470) d](/filings/0001701478-25-000012.md) | [(2,961)](/filings/0001701478-25-000018.md) | [(2,660)](/filings/0001701478-25-000040.md) | [(2,929)](/filings/0001701478-25-000050.md) | [(2,434) d](/filings/0001701478-26-000013.md) | [(3,100)](/filings/0001701478-26-000028.md) | [(2,871)](/filings/0001701478-26-000037.md) | [(2,768)](/filings/0001701478-25-000050.md) | [(2,227) d](/filings/0001701478-26-000013.md) | [(3,934)](/filings/0001701478-26-000028.md) | [(3,419)](/filings/0001701478-26-000037.md) |
| Interest expense | $k | [0.7](/filings/0001493152-23-041056.md) | [1.0 d](/filings/0001493152-24-010091.md) | [0.9](/filings/0001701478-24-000005.md) | [1.8](/filings/0001701478-25-000040.md) | [3.9](/filings/0001701478-25-000050.md) | [5.6 d](/filings/0001701478-26-000013.md) | [1.3](/filings/0001701478-26-000028.md) | [0.5](/filings/0001701478-26-000037.md) | [0.4](/filings/0001701478-25-000050.md) | [5.5 d](/filings/0001701478-26-000013.md) | [3.4](/filings/0001701478-26-000028.md) | [1.4](/filings/0001701478-26-000037.md) |
| Income tax | $k | [0.0](/filings/0001701478-24-000012.md) | [7.6 d](/filings/0001701478-25-000012.md) | [0.0](/filings/0001701478-25-000018.md) | [0.0](/filings/0001701478-25-000040.md) | [0.0](/filings/0001701478-25-000050.md) | [9.0 d](/filings/0001701478-26-000013.md) | [0.0](/filings/0001701478-26-000028.md) | [0.0](/filings/0001701478-26-000037.md) | [0.0](/filings/0001701478-25-000050.md) | [8.3 d](/filings/0001701478-26-000013.md) | [0.0](/filings/0001701478-26-000028.md) | [0.0](/filings/0001701478-26-000037.md) |
| Net income | $k | [(1,943)](/filings/0001701478-24-000012.md) | [(2,454) d](/filings/0001701478-25-000012.md) | [(2,933)](/filings/0001701478-25-000050.md) | [(2,632)](/filings/0001701478-25-000050.md) | [(1,009)](/filings/0001701478-25-000050.md) | [(2,393) d](/filings/0001701478-26-000013.md) | [(3,068)](/filings/0001701478-26-000037.md) | [(2,889)](/filings/0001701478-26-000037.md) | [(2,765)](/filings/0001701478-25-000050.md) | [(2,234) d](/filings/0001701478-26-000013.md) | [(3,927)](/filings/0001701478-26-000037.md) | [(3,348)](/filings/0001701478-26-000037.md) |
| Diluted EPS | $ per share | [(4.82)](/filings/0001701478-24-000012.md) | not reported | [(4.32)](/filings/0001701478-25-000018.md) | [(2.74)](/filings/0001701478-25-000040.md) | [(1.14)](/filings/0001701478-25-000050.md) | not reported | [(1.55)](/filings/0001701478-26-000028.md) | [(1.18)](/filings/0001701478-26-000037.md) | [(0.67)](/filings/0001701478-25-000050.md) | not reported | [(0.25)](/filings/0001701478-26-000028.md) | [(0.17)](/filings/0001701478-26-000037.md) |
| Basic EPS | $ per share | [(4.82)](/filings/0001701478-24-000012.md) | not reported | [(4.32)](/filings/0001701478-25-000018.md) | [(2.74)](/filings/0001701478-25-000040.md) | [(1.14)](/filings/0001701478-25-000050.md) | not reported | [(1.55)](/filings/0001701478-26-000028.md) | [(1.18)](/filings/0001701478-26-000037.md) | [(0.67)](/filings/0001701478-25-000050.md) | not reported | [(0.25)](/filings/0001701478-26-000028.md) | [(0.17)](/filings/0001701478-26-000037.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.4](/filings/0001493152-23-041056.md) | [1.8](/filings/0001701478-25-000012.md) | [3.0](/filings/0001701478-24-000005.md) | [0.8](/filings/0001701478-24-000009.md) | [7.3](/filings/0001701478-24-000012.md) | [4.6](/filings/0001701478-26-000013.md) | [3.2](/filings/0001701478-25-000018.md) | [1.0](/filings/0001701478-25-000040.md) | [1.4](/filings/0001701478-25-000050.md) | [2.1](/filings/0001701478-26-000037.md) | [10.1](/filings/0001701478-26-000028.md) | [6.7](/filings/0001701478-26-000037.md) |
| Current assets | $m | [4.9](/filings/0001493152-23-041056.md) | [2.5](/filings/0001701478-25-000012.md) | [3.5](/filings/0001701478-24-000005.md) | [1.3](/filings/0001701478-24-000009.md) | [7.6](/filings/0001701478-24-000012.md) | [5.2](/filings/0001701478-26-000013.md) | [3.9](/filings/0001701478-25-000018.md) | [1.8](/filings/0001701478-25-000040.md) | [2.2](/filings/0001701478-25-000050.md) | [3.0](/filings/0001701478-26-000037.md) | [10.8](/filings/0001701478-26-000028.md) | [7.4](/filings/0001701478-26-000037.md) |
| Total assets | $m | [7.5](/filings/0001493152-23-041056.md) | [5.1](/filings/0001701478-25-000012.md) | [6.1](/filings/0001701478-24-000005.md) | [3.9](/filings/0001701478-24-000009.md) | [9.8](/filings/0001701478-24-000012.md) | [7.4](/filings/0001701478-26-000013.md) | [5.9](/filings/0001701478-25-000018.md) | [4.0](/filings/0001701478-25-000040.md) | [4.3](/filings/0001701478-25-000050.md) | [5.0](/filings/0001701478-26-000037.md) | [12.1](/filings/0001701478-26-000028.md) | [8.9](/filings/0001701478-26-000037.md) |
| Current liabilities | $m | [1.5](/filings/0001493152-23-041056.md) | [1.6](/filings/0001701478-25-000012.md) | [1.3](/filings/0001701478-24-000005.md) | [1.7](/filings/0001701478-24-000009.md) | [1.4](/filings/0001701478-24-000012.md) | [1.4](/filings/0001701478-26-000013.md) | [1.3](/filings/0001701478-25-000018.md) | [1.5](/filings/0001701478-25-000040.md) | [1.8](/filings/0001701478-25-000050.md) | [1.1](/filings/0001701478-26-000037.md) | [1.5](/filings/0001701478-26-000028.md) | [1.5](/filings/0001701478-26-000037.md) |
| Total liabilities | $m | [2.2](/filings/0001493152-23-041056.md) | [2.2](/filings/0001701478-25-000012.md) | [1.7](/filings/0001701478-24-000005.md) | [2.2](/filings/0001701478-24-000009.md) | [1.7](/filings/0001701478-24-000012.md) | [1.7](/filings/0001701478-26-000013.md) | [1.5](/filings/0001701478-25-000018.md) | [1.7](/filings/0001701478-25-000040.md) | [2.0](/filings/0001701478-25-000050.md) | [1.2](/filings/0001701478-26-000037.md) | [1.6](/filings/0001701478-26-000028.md) | [1.6](/filings/0001701478-26-000037.md) |
| Shareholders' equity | $m | [5.3](/filings/0001701478-24-000012.md) | [2.9](/filings/0001701478-26-000013.md) | [4.3](/filings/0001701478-25-000050.md) | [1.7](/filings/0001701478-25-000050.md) | [8.1](/filings/0001701478-25-000050.md) | [5.7](/filings/0001701478-26-000037.md) | [4.4](/filings/0001701478-26-000037.md) | [2.2](/filings/0001701478-26-000037.md) | [2.3](/filings/0001701478-25-000050.md) | [3.8](/filings/0001701478-26-000037.md) | [10.5](/filings/0001701478-26-000037.md) | [7.3](/filings/0001701478-26-000037.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,792) d](/filings/0001701478-24-000012.md) | [(2,539) d](/filings/0001701478-25-000012.md) | [(3,020)](/filings/0001701478-25-000018.md) | [(2,102) d](/filings/0001701478-25-000040.md) | [(2,476) d](/filings/0001701478-25-000050.md) | [(2,586) d](/filings/0001701478-26-000013.md) | [(3,072)](/filings/0001701478-26-000028.md) | [(2,815) d](/filings/0001701478-26-000037.md) | [(2,445) d](/filings/0001701478-25-000050.md) | [(2,893) d](/filings/0001701478-26-000013.md) | [(2,477)](/filings/0001701478-26-000028.md) | [(3,291) d](/filings/0001701478-26-000037.md) |
| Capital expenditure | $k | [5.3 d](/filings/0001701478-24-000012.md) | [3.7 d](/filings/0001701478-25-000012.md) | [0.0](/filings/0001701478-24-000005.md) | [0.0 d](/filings/0001701478-25-000040.md) | [8.6 d](/filings/0001701478-25-000050.md) | [0.0 d](/filings/0001701478-26-000013.md) | [0.0](/filings/0001701478-26-000028.md) | [11.6 d](/filings/0001701478-26-000037.md) | [3.4 d](/filings/0001701478-25-000050.md) | [9.2 d](/filings/0001701478-26-000013.md) | [14.9](/filings/0001701478-26-000028.md) | [40.1 d](/filings/0001701478-26-000037.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.1](/filings/0001493152-23-041056.md) | [1.1](/filings/0001701478-24-000005.md) | [0.1](/filings/0001701478-24-000009.md) | [0.4](/filings/0001701478-24-000012.md) | [0.7](/filings/0001701478-25-000018.md) | [1.0](/filings/0001701478-25-000040.md) | [0.9](/filings/0001701478-25-000050.md) | [2.0](/filings/0001701478-26-000028.md) | [2.4](/filings/0001701478-26-000037.md) | [4.1](/filings/0001701478-25-000050.md) | [15.5](/filings/0001701478-26-000028.md) | [19.3](/filings/0001701478-26-000037.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 60,603,742 at 2026-08-11, from the cover of the [10-Q filed 2026-08-12](/filings/0001701478-26-000037.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.